PDS Biotechnology (NASDAQ:PDSB) Releases Earnings Results, Misses Estimates By $0.09 EPS

PDS Biotechnology (NASDAQ:PDSB – Get Rating) released its quarterly earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09), MarketWatch Earnings reports. During the same quarter last year, the business posted ($0.14) earnings per share.

Shares of PDSB traded up $0.73 during midday trading on Friday, reaching $4.56. 552,690 shares of the stock were exchanged, compared to its average volume of 232,316. PDS Biotechnology has a 12-month low of $3.47 and a 12-month high of $17.85. The firm has a 50 day simple moving average of $5.66 and a 200-day simple moving average of $7.26.

Several institutional investors and hedge funds have recently bought and sold shares of PDSB. Morgan Stanley raised its stake in shares of PDS Biotechnology by 2,254.9% during the 2nd quarter. Morgan Stanley now owns 65,703 shares of the company’s stock worth $825,000 after purchasing an additional 62,913 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of PDS Biotechnology during the 3rd quarter worth about $170,000. UBS Group AG bought a new position in shares of PDS Biotechnology in the 3rd quarter valued at approximately $44,000. Northern Trust Corp raised its stake in shares of PDS Biotechnology by 6.3% in the 4th quarter. Northern Trust Corp now owns 41,820 shares of the company’s stock valued at $339,000 after acquiring an additional 2,466 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of PDS Biotechnology by 7,093.1% in the 4th quarter. Bank of America Corp DE now owns 4,172 shares of the company’s stock valued at $34,000 after acquiring an additional 4,114 shares in the last quarter. 20.94% of the stock is owned by institutional investors.

A number of research firms recently weighed in on PDSB. Noble Financial reiterated a “buy” rating and issued a $22.00 price target on shares of PDS Biotechnology in a research report on Thursday. StockNews.com upgraded PDS Biotechnology to a “sell” rating in a research report on Saturday, April 9th. Zacks Investment Research lowered PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Alliance Global Partners decreased their price objective on PDS Biotechnology from $18.00 to $16.00 in a research report on Friday. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Buy” and an average price target of $17.00.

About PDS Biotechnology (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Featured Articles